文献速递类风湿关节炎

多普勒超声预测类风湿关节炎临床缓解患者成功停用生物DMARDs

Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究纳入119例持续缓解且无影像学进展的RA患者,按标准化方案递减bDMARDs,基线行24关节超声等评估。2年随访显示,IgM-RF阴性及较低多普勒总评分是成功停药的独立预测因素,多普勒总评分每增加1单位成功停药几率降低56%;超声不能预测成功减量。

要点

  • 多普勒超声总评分是RA患者2年成功停用bDMARDs的独立预测因素。
  • 多普勒总评分每增加1单位,成功停药几率降低56%。
  • 超声不能预测bDMARDs成功减量,既往bDMARDs数量可预测减量。

核心结论

  • 多普勒总评分是2年随访时成功停用bDMARDs的独立预测因素,每增加1单位成功停药几率降低56%。
  • 超声不能预测成功减量。

研究设计与样本

  • 纳入119例持续缓解(DAS28-CRP≤2.6)且前一年无影像学进展的RA患者,按标准化方案递减bDMARDs。
  • 基线行临床评估、MRI、X线及24关节超声,超声滑膜炎采用OMERACT评分系统对灰阶和多普勒活动分别行0-3分关节水平评分并计算患者水平总评分。
  • 2年后评估最终治疗状态,采用逻辑回归分析超声指标对成功减量和停药的预测价值。

主要发现

  • IgM-RF阴性(OR=0.29,95%CI:0.10-0.85;P=0.024)和较低24关节多普勒总评分(OR=0.44,95%CI:0.15-0.87;P=0.014)是2年随访成功停用bDMARDs的独立预测因素。
  • 多普勒总评分的预测价值独立于MRI表现。
  • 既往bDMARDs数量可预测成功减量(OR=0.58,95%CI:0.35-0.91;P=0.018),而超声不能预测减量。
  • 临床参数不能预测成功减量或停药。

关键数值与推荐

  • 持续缓解定义为DAS28-CRP≤2.6且前一年无影像学进展。
  • 超声滑膜炎采用OMERACT评分系统,关节水平灰阶和多普勒活动均评0-3分,计算24关节患者水平总评分。

临床怎么用

  • 对持续缓解的RA患者,可参考24关节多普勒超声总评分及IgM-RF状态评估停用bDMARDs的成功可能性。
  • 多普勒总评分较高者成功停药几率降低,决策时需结合其他临床因素。
  • 超声不适用于预测bDMARDs减量成功,减量决策可参考既往bDMARDs数量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the ability of ultrasound to predict successful tapering and successful discontinuation of biological DMARDs (bDMARDs) at the 2-year follow-up in RA patients in sustained remission. METHODS: Patients in sustained remission (DAS28-CRP ≤ 2.6) and with no radiographic progression the previous year tapered bDMARDs according to a standardized regime. A total of 119 of these patients were included in this ultrasound substudy. At baseline, clinical assessment, MRI, X-ray and ultrasound of 24 joints were performed. Ultrasound-detected synovitis was defined and scored 0-3 using the OMERACT scoring system at the joint level for both grey-scale and Doppler activity. Sum scores for each ultrasound modality were calculated for 24 joints at the patient level. The final state of treatment was assessed after 2 years. The predictive value of ultrasound measures for successful tapering and discontinuation at the 2-year follow-up was assessed via logistic regression analyses. RESULTS: Negative IgM-RF [odds ratio (OR) = 0.29, 95% CI: 0.10-0.85; P = 0.024] and lower Doppler sum score of 24 joints (OR = 0.44, 95% CI: 0.15, 0.87; P = 0.014) were independent predictors for successful discontinuation of bDMARDs at the 2-year follow-up. The predictive value of the Doppler sum score was independent of MRI findings. Previous numbers of bDMARDs were predictive of successful tapering (OR = 0.58, 95% CI: 0.35, 0.91; P = 0.018), whereas ultrasound was not. Clinical parameters were not predictive of successful tapering/discontinuation. CONCLUSION: Doppler sum score was an independent predictor for successful discontinuation of bDMARDs at the 2-year follow-up-the odds for achieving successful discontinuation decreased by 56% per one-unit increase in Doppler sum score. Ultrasound could not predict successful tapering.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Terslev L, Brahe CH, Hetland ML, et al. Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission. Rheumatology (Oxford). 2021. PMID: 33748831. doi:10.1093/rheumatology/keab276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。